These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
146 related articles for article (PubMed ID: 7914055)
21. Clozapine: current status and role in the pharmacotherapy of schizophrenia. Remington GJ; Addington D; Collins EJ; Jones BD; Lalonde P; MacCrimmon DJ; MacEwan GW Can J Psychiatry; 1996 Apr; 41(3):161-6. PubMed ID: 8722645 [TBL] [Abstract][Full Text] [Related]
22. Negative symptoms, tardive dyskinesia and depression in chronic schizophrenia. Barnes TR; Liddle PF; Curson DA; Patel M Br J Psychiatry Suppl; 1989 Nov; (7):99-103. PubMed ID: 2575915 [No Abstract] [Full Text] [Related]
23. [Is there a special indication for fluphenazine in therapy refractory hallucinations?]. Bechter K Nervenarzt; 1994 Nov; 65(11):798-801. PubMed ID: 7816159 [TBL] [Abstract][Full Text] [Related]
24. Obsessive-compulsive symptoms in schizophrenia: their relationship with clinical features and pharmacological treatment. Nolfe G; Milano W; Zontini G; Petrella C; De Rosa M; Rundle-Smith S; Nolfe G J Psychiatr Pract; 2010 Jul; 16(4):235-42. PubMed ID: 20644358 [TBL] [Abstract][Full Text] [Related]
25. New antipsychotic medications: do research results relate to clinical practice? MacEwan GW Can J Psychiatry; 1993 Sep; 38 Suppl 3():S75-9. PubMed ID: 7504572 [TBL] [Abstract][Full Text] [Related]
26. [Psychopathologic and cognitive investigations in schizophrenia]. Farkas M Orv Hetil; 2009 Mar; 150(9):423-9. PubMed ID: 19228571 [TBL] [Abstract][Full Text] [Related]
27. Conceptualizing schizophrenia through attenuated symptoms in the population. Carpenter WT Am J Psychiatry; 2010 Sep; 167(9):1013-6. PubMed ID: 20826849 [No Abstract] [Full Text] [Related]
31. Lifelong course of positive and negative symptoms in chronically institutionalized patients with schizophrenia. Mancevski B; Keilp J; Kurzon M; Berman RM; Ortakov V; Harkavy-Friedman J; Rosoklija G; Dwork AJ Psychopathology; 2007; 40(2):83-92. PubMed ID: 17215594 [TBL] [Abstract][Full Text] [Related]
32. [Subjective view of positive symptoms and quality of life in patients with schizophrenia]. Karow A; Schäfer I; Hirdes F; Osterwald C; Naber D Psychiatr Prax; 2008 Sep; 35(6):286-93. PubMed ID: 18504688 [TBL] [Abstract][Full Text] [Related]
33. Treatment of late-life schizophrenia with neuroleptics. Jeste DV; Lacro JP; Gilbert PL; Kline J; Kline N Schizophr Bull; 1993; 19(4):817-30. PubMed ID: 7905663 [TBL] [Abstract][Full Text] [Related]
34. Implications for the pharmacotherapy of schizophrenia. Rep Group Adv Psychiatry; 1992; (134):35-58. PubMed ID: 1348372 [No Abstract] [Full Text] [Related]
35. A double-blind, randomized study comparing the efficacy and safety of sertindole and risperidone in patients with treatment-resistant schizophrenia. Kane JM; Potkin SG; Daniel DG; Buckley PF J Clin Psychiatry; 2011 Feb; 72(2):194-204. PubMed ID: 20673553 [TBL] [Abstract][Full Text] [Related]
36. Tardive dyskinesia and type II schizophrenia. Davis EJ; Borde M; Sharma LN Br J Psychiatry; 1992 Feb; 160():253-6. PubMed ID: 1347240 [TBL] [Abstract][Full Text] [Related]
37. Overcoming the neuroleptic-induced deficit syndrome: clinical observations with remoxipride. Lewander T Acta Psychiatr Scand Suppl; 1994; 380():64-7. PubMed ID: 7914053 [TBL] [Abstract][Full Text] [Related]
38. Auditory hallucinations suppressed by etizolam in a patient with schizophrenia. Benazzi F; Mazzoli M; Rossi E Can J Psychiatry; 1993 Oct; 38(8):574-5. PubMed ID: 7902201 [TBL] [Abstract][Full Text] [Related]
39. The effect of psychopathology on the ability of schizophrenic patients to give informed consent. Schachter D; Kleinman I; Prendergast P; Remington G; Schertzer S J Nerv Ment Dis; 1994 Jun; 182(6):360-2. PubMed ID: 7911156 [No Abstract] [Full Text] [Related]